Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TetraVax-DV TV005 in flavivirus-naïve adults 50-70 years of age
NCT02879266Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2016
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dengue fever comparing TetraVax-DV TV005 with Placebo (2 arms). Primary endpoint: Frequency of TV005-related adverse events at 180 days. Started Feb 2016; status: completed.
02
Drugs
TetraVax-DV
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02879266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879266.